Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Completed · Phase 1

Conditions studied: Migraine

In brief

This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.

Key facts

Study ID

NCT04179474

Run by

Allergan

People needed

40

Starts

2019-09-26

Expected to finish

2019-12-23

Last updated by the study team

2021-03-10

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3, 2018)
• By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
• History of at least 2 migraine attacks per month in the 2 months prior to Screening
• Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital sign assessment at the Screening Visit. Clinical site may perform a maximum of 2 repeats of vital sign measurements if the initial measurement is out of range.
• Negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, cannabinoids, opiates, and phencyclidine at the Screening Visit and Day -1; unless explained by concomitant medication use (eg, opioids prescribed for migraine pain)
• Participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period

You may not qualify if…

• Difficulty distinguishing migraine headache from tension-type or other headaches
• Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3
• Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3
• Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Screening
• Has a chronic non-headache pain condition requiring daily pain medication (with the exception of pregabalin)
• Has clinically significant cardiovascular or cerebrovascular disease per the investigator's opinion
• Previously participated in an investigational study of ubrogepant
• Participation in any other clinical investigation using an experimental drug within 30 days prior to study intervention administration
• Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration

Where it is running

• QPS — Springfield, Missouri, United States
• Spaulding — West Bend, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.